Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Krystal Biotech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Krystal Biotech's regulatory disclosures and financial reporting.
Krystal Biotech reported solid profitability and growth for the quarter ended June 30, 2026. Product revenue, net was $119.2 million versus $96.0 million a year earlier, driven by VYJUVEK, which generated $119.2 million in global net product revenue in the quarter and $965.9 million since launch, with a gross margin of 95%. Quarterly net income was $54.8 million, or $1.85 basic and $1.79 diluted EPS, compared with $38.3 million and EPS of $1.33 basic and $1.29 diluted in the prior-year quarter. For the first six months of 2026, product revenue, net totaled $235.6 million and net income was $110.7 million.
Cash, cash equivalents and investments totaled $1.1 billion as of June 30, 2026, supporting a broad pipeline. Key upcoming milestones include a registrational IOLITE readout for KB803 in 4Q 2026, continued EMERALD-1 enrollment for KB801, advancement of KB407 toward a registrational study in 2027, interim data for KB111 and KB407/KB408 programs, and further development of KB707 in NSCLC and Gorlin syndrome. The company guided full-year 2026 non-GAAP combined R&D and SG&A expense to $175.0–$195.0 million, excluding stock-based compensation, while continuing global VYJUVEK expansion, including anticipated launches in Spain and Italy in 2026.
Krystal Biotech, Inc. reported that on July 21, 2026 it submitted a response to a U.S. Patent and Trademark Office Office Action for a published patent application covering KB801, its investigational gene therapy for neurotrophic keratitis. The response includes data from a single patient in a discontinued clinical study who, after receiving KB801, experienced complete closure of a persistent corneal epithelial defect. The study was discontinued to advance KB801 into a pivotal trial, and no safety concerns or serious adverse events were observed in patients treated in that study.
Krystal Biotech explains that this single-patient observation had not been previously shared and is being disclosed so investors and other stakeholders have equal access to information that will appear in the patent prosecution record. The company emphasizes that this anecdotal result is not top-line data from any clinical trial and that no conclusions about the safety or efficacy of KB801 should be drawn from it. Krystal Biotech does not plan to provide subject-level updates from the discontinued study and expects to report pivotal trial results in the ordinary course. The described information and an image of the defect closure, furnished as an exhibit, are treated as furnished rather than filed under the Exchange Act and are not incorporated into other SEC reports except by specific reference, and the company notes forward-looking statements remain subject to clinical and other risks outlined in its risk factor disclosures.
Krystal Biotech EVP and General Counsel Thomas John Charles reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 1,000 shares of common stock at $179.25 per share and then sold 1,000 shares in an open-market transaction at $347.27 per share, leaving him with no directly held common shares. Following the derivative transaction, he continued to hold 6,500 stock options expiring on February 27, 2035. According to a footnote, both the acquisition and sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026, and that plan has now fully completed and terminated.
KRYS filing reports a stock option exercise and planned sale of 1,000 shares of Common Stock on 06/25/2026. The report also lists a prior sale of 642 shares on 05/26/2026 for $193,903.26. The transactions are reported through Fidelity Brokerage Services LLC and indicate cash as the consideration method for the 1,000-share item.
Krystal Biotech, Inc. director and President, R&D Suma Krishnan reported open-market sales of 25,000 shares of common stock. The transactions took place on June 4, 2026 in multiple trades at prices generally ranging from about $300.75 to $311.65 per share.
The filing states that these sales were made under a pre-established Rule 10b5-1 trading plan adopted on September 4, 2025, which began on December 4, 2025 and is scheduled to run until December 4, 2026 unless completed earlier. Krishnan also reports indirect ownership of 50,000 shares through the Krishnan Family Trust and 90,000 shares through the Krishnan Spousal Trust.
Krystal Biotech, Inc.’s President and CEO Krish S. Krishnan reported open-market sales of 25,000 shares of common stock on June 4, 2026. The shares were sold in multiple trades with reported weighted average prices such as $312.23 and $300.75 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025, which began on December 4, 2025 and is scheduled to terminate on December 4, 2026 or earlier under its terms. After these transactions, Krishnan directly holds 1,450,253 shares and indirectly holds 90,000 shares through the SMK Trust FBO KSK and 50,000 shares through the Krishnan Family Trust, where he shares voting and investment power. Shares directly owned by his spouse are reported separately and are disclaimed except for any pecuniary interest.
Krystal Biotech, Inc. executive vice president and general counsel Thomas John Charles sold 642 shares of common stock in an open-market transaction. The shares were sold at an average price of $302.03 per share on May 26, 2026, and his directly held common stock position reported in this filing is now zero shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026, which is scheduled to run through December 31, 2026 unless it terminates earlier under its terms.